pharmaphorum.com
Cure8 news brief
Why This Matters
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect treatment choices and insurance coverage discussions.
Who Should Pay Attention
Adults with Crohn’s disease, especially those who have failed other biologics or immunosuppressants; clinicians who treat IBD; patients currently on or considering IL-23 therapies; IBD researchers and policy/market watchers.
Study Snapshot
Story typeCompany update
Evidence typeRegulatory update
Source depthFull source text
What To Know
Lilly’s Omvoh (mirikizumab), an IL-23 inhibitor already approved for ulcerative colitis, received FDA approval for moderately to severely active Crohn’s disease based on the VIVID-1 trial and supporting VIVID-2 extension data.
The article summarizes trial remission and endoscopic response numbers and positions Omvoh within the competitive IL-23 class alongside Skyrizi (risankizumab), Stelara (ustekinumab), Tremfya (guselkumab) and Ilumya (tildrakizumab). It also notes the drug’s prior UC approvals, ongoing submissions in other regions, and commercial context and projections.
Keep In Mind
This is a regulatory approval news item based on clinical trial results (VIVID program) reported in the article. The piece includes commercial analysis and comparisons with other IL-23 drugs; it does not provide prescribing guidance.
Real-world availability, formulary coverage, and how Omvoh compares clinically to other approved options will depend on regulatory labels, guideline updates, and payer decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationpharmaphorum.com
Indexed viaBing News
Source typeCompany update
PublishedJan 16, 2025, 2:04 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
J&J adds to IL-23 options in Crohn's after FDA approval
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.